Using deep learning to predict how T cells recognize cancer targets

Applying deep learning to predict T cell receptor binding specificity of neoantigens and response to checkpoint inhibitors

NIH-funded research Ut Southwestern Medical Center · NIH-11072125

This study is exploring how T cells, which help fight cancer, recognize special markers on cancer cells, and it aims to use smart computer techniques to find out which markers can best activate these T cells to improve cancer treatments for patients.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUt Southwestern Medical Center NIH-funded
Lab location1 site (Dallas, United States)
Project IDNIH-11072125 on NIH RePORTER

What this research studies

This research focuses on understanding how T cells recognize neoantigens, which are unique markers on cancer cells. By applying advanced deep learning techniques, the project aims to predict which neoantigens can effectively trigger T cell responses and how these responses relate to cancer treatments known as checkpoint inhibitors. The study will develop models that can analyze neoantigen data to improve the effectiveness of immunotherapy for cancer patients. This approach seeks to fill gaps in current knowledge about T cell receptor binding and the immunogenicity of neoantigens.

Who could benefit from this research

Good fit: Ideal candidates for this research are cancer patients who are being considered for immunotherapy treatments.

Not a fit: Patients with cancers that do not express neoantigens or those not eligible for immunotherapy may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more personalized and effective cancer immunotherapies for patients.

How similar studies have performed: Previous research has shown promise in using computational models to predict immune responses, suggesting that this approach could yield significant advancements.

Where this research is happening

Dallas, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapyanticancer immunotherapy
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.